# US 8,785,606 B2 · Compositions and methods for promoting neuronal outgrowth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,606 B2
- Document ID: US8785606B2
- Status: Granted
- Kind: B2
- Application number: 13/451,968
- Filed: 2012-04-20
- Published: 2012-08-16
- Granted: 2014-07-22
- Earliest claimed: 2002-05-04
- Assignees: Acorda Therapeutics, Inc.
- Applicants: Elliott A. Gruskin; Jennifer F. Iaci; Andrea M. Vecchione; Sarah J. Kasperbauer; Gargi Roy
- Inventors: Elliott A. Gruskin; Jennifer F. Iaci; Andrea M. Vecchione; Sarah J. Kasperbauer; Gargi Roy
- Web page: https://patentgrep.com/patent/US8785606B2

## CPC

- A61K 38/51: Lyases (4)
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 9/88: Lyases (4.)
- C12Y 402/02005: Chondroitin AC lyase (4.2.2.5)
- C12Y 402/02019: Chondroitin B lyase (4.2.2.19)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

## Claims

### Claim 1

A method of treating a mammal having a spinal cord injury comprising administering an effective amount of chondroitinase AC, chondroitinase B, or a mixture thereof to the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein administering is selected from topical, local and systemic.

### Claim 3 (depends on 1)

The method of claim 1, wherein chondroitinase AC is administered.

### Claim 4 (depends on 3)

The method of claim 3, wherein the chondroitinase AC is selected from the group consisting of chondroitinase AC, chondroitinase AC II and chondroitinase AC III.

### Claim 5 (depends on 1)

The method of claim 1, wherein chondroitinase B is administered.

### Claim 6 (depends on 1)

The method of claim 1, wherein a combination of a chondroitinase AC and chondroitinase B is administered.

### Claim 7 (depends on 1)

The method of claim 1, wherein the chondroitinase AC, chondroitinase B or a mixture thereof is administered as a composition comprising a pharmaceutically acceptable carrier.

### Claim 8 (depends on 2)

The method of claim 2, wherein local administration uses a mode selected from a catheter, a syringe, and direct application to the injury.

### Claim 9 (depends on 1)

The method of claim 1, wherein the effective amount is administered in multiple doses.

### Claim 10 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 11

A method of promoting neurite outgrowth in a mammal having a spinal cord injury comprising administering an effective amount of chondroitinase AC, chondroitinase B, or a mixture thereof to the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the neurite outgrowth is in the central nervous system.

### Claim 13 (depends on 11)

The method of claim 11, wherein administering is selected from topical, local and systemic.

### Claim 14 (depends on 11)

The method of claim 11, wherein chondroitinase AC is administered.

### Claim 15 (depends on 14)

The method of claim 14, wherein the chondroitinase AC is selected from the group consisting of chondroitinase AC, chondroitinase AC II and chondroitinase AC III.

### Claim 16 (depends on 11)

The method of claim 11, wherein chondroitinase B is administered.

### Claim 17 (depends on 11)

The method of claim 11, wherein a combination of a chondroitinase AC and chondroitinase B is administered.

### Claim 18 (depends on 11)

The method of claim 11, wherein the chondroitinase AC, chondroitinase B or a mixture thereof is administered as a composition comprising a pharmaceutically acceptable carrier.

### Claim 19 (depends on 13)

The method of claim 13, wherein local administration uses a mode selected from a catheter, a syringe, and direct application to the injury.

### Claim 20 (depends on 11)

The method of claim 11, wherein the effective amount is administered in multiple doses.

### Claim 21 (depends on 11)

The method of claim 11, wherein the mammal is a human.